Shanghai Hengrui Pharmaceutical Co., Ltd.

This early-phase study tests a new drug called SHR-3836 in 99 adults with multiple myeloma that has returned or stopped responding to standard treatments. The main goals are to find the safest dose and check for side effects, while also seeing if the drug can shrink tumors. Parti…

This Phase 3 trial tests a new drug, SHR-A1904, in 524 people with advanced stomach or gastroesophageal junction cancer that has a specific protein (CLDN18.2). Participants receive either SHR-A1904 or standard chemotherapy. The main goal is to see if the new drug helps people liv…

This study tests a new drug called SHR-9839, given with other cancer treatments, for people with advanced solid tumors that have not responded to standard therapy. The goal is to see if the combination is safe and can shrink tumors. About 156 adults aged 18-75 with certain cancer…

This study tests a combination of two experimental drugs, SHR-1501 and adbelizumab, in people with advanced or metastatic solid tumors that have not responded to standard treatments. The goal is to find a safe dose and see if the combination can shrink tumors. About 203 adults ag…

This study tests a new drug called HRS-4642 combined with other cancer treatments for people with advanced pancreatic cancer that cannot be removed by surgery. About 60 adults aged 18 to 75 will take part. The goal is to see if the combination is safe and helps control the cancer…

This study is testing an experimental drug called SHR-7787 combined with other anti-cancer medicines in 400 people with advanced solid tumors that cannot be removed by surgery. The goal is to find safe doses and see if the combination can shrink tumors or slow cancer growth. Part…

This study tests a new drug called SHR-A1904, given together with chemotherapy and immunotherapy, for people with advanced solid tumors that have a specific protein called CLDN18.2. The goal is to see if the combination is safe and works better than standard treatment. About 924 …

This study tests a new drug called SHR-A2102 combined with the immunotherapy adebrelimab, with or without chemotherapy or bevacizumab, in 248 people with advanced or metastatic non-small cell lung cancer. The goal is to find the safest dose and see if the combination can shrink t…

This study tests a new drug called SHR-7367 combined with other cancer treatments for people with advanced solid tumors. The goal is to find the safest dose and see if the combination can shrink tumors. About 100 adults aged 18 to 75 with measurable tumors and good organ function…

This study tests a new drug called SHR-A2102 combined with other cancer treatments for people with a type of lung cancer that can be removed by surgery. The goal is to see if the combination can destroy more cancer cells before and after the operation, helping patients live longe…

This early-phase study is testing a new drug, HRS-6257, in 80 healthy adults to see if it is safe and how the body processes it. Participants will receive either the drug or a placebo, and researchers will monitor side effects and measure drug levels in the blood. The study also …